UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 392

Sortiert nach

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

Cancer research (Chicago, Ill.), 2007-01, Vol.67 (2), p.746-755

2007

Volltextzugriff (PDF)

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

Microvascular research, 2009-03, Vol.77 (2), p.78-86

2009

Volltextzugriff (PDF)

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Blood, 2001-07, Vol.98 (1), p.210-216

2001

Volltextzugriff (PDF)

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

The Journal of pharmacology and experimental therapeutics, 2003-06, Vol.305 (3), p.1222

2003

Volltextzugriff (PDF)

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

Journal of medicinal chemistry, 2009-03, Vol.52 (6), p.1522-1524

2009

Volltextzugriff (PDF)

CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity

The Journal of surgical research, 2010-11, Vol.164 (1), p.116-125

2010

Volltextzugriff (PDF)

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-a Inhibitor

Journal of medicinal chemistry, 2009-03, Vol.52 (6), p.1522-1524

2009

Volltextzugriff (PDF)

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

Journal of translational medicine, 2007-07, Vol.5 (1), p.38-38, Article 38

2007

Volltextzugriff (PDF)

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (18), p.7347-7356

2009

Volltextzugriff (PDF)

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

The Journal of immunology (1950), 2002-05, Vol.168 (10), p.4914-4919

2002

Volltextzugriff (PDF)

A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay

Journal of translational medicine, 2004-01, Vol.2 (1), p.4-4

2004

Volltextzugriff (PDF)

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.951-959

2006

Volltextzugriff (PDF)

Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells

Pancreas, 2009-01, Vol.38 (1), p.78-84

2009

Volltextzugriff (PDF)

A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

Cancer research (Chicago, Ill.), 2003-02, Vol.63 (3), p.593-599

2003

Volltextzugriff (PDF)

Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity

Journal of medicinal chemistry, 1996-08, Vol.39 (17), p.3238-3240

1996

Volltextzugriff (PDF)

Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Oncology research, 2003, Vol.14 (2), p.75

2003

Volltextzugriff (PDF)

Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition

Cancer research (Chicago, Ill.), 2003-12, Vol.63 (23), p.8073-8078

2003

Volltextzugriff (PDF)

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

The Journal of immunology (1950), 1999-07, Vol.163 (1), p.380-386

1999

Volltextzugriff (PDF)

Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Bioorganic & medicinal chemistry letters, 1999-06, Vol.9 (11), p.1625-1630

1999

Volltextzugriff (PDF)

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues

Journal of clinical immunology, 2001-09, Vol.21 (5), p.357-364

2001

Volltextzugriff (PDF)

Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner

Cellular immunology, 2004-08, Vol.230 (2), p.81-88

2004

Volltextzugriff (PDF)

Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-AT

Journal of interferon & cytokine research, 2005-10, Vol.25 (10), p.604-616

2005

Volltextzugriff (PDF)

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Molecular medicine (Cambridge, Mass.), 1996-07, Vol.2 (4), p.506-515

1996

Volltextzugriff (PDF)

Carboxylic acid replacement structure-activity relationships in suosan type sweeteners. A sweet taste antagonist. 1

Journal of medicinal chemistry, 1992-05, Vol.35 (10), p.1747-1751

1992

Volltextzugriff (PDF)

Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34 super(+) Progenitor Cells

Cancer research (Chicago, Ill.), 2007-01, Vol.67 (2), p.746-755

2007

Volltextzugriff (PDF)

1 – 25 von 392

Suche als RSS-Feed

Aktive Filter

ThemaAdult

ThemaChemistry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(300)
Mit Volltextzugriff
(348)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(194)
Life Sciences & Biomedicine
(132)
Humans
(108)
Biological And Medical Sciences
(49)
Animals
(43)
Medical Sciences
(43)
Physics
(39)
Physical Sciences
(38)
Female
(35)
Male
(33)
Physics, Particles & Fields
(29)
High Energy Physics - Experiment
(27)
Mice
(25)
Pharmacology. Drug Treatments
(19)
Thalidomide - Analogs & Derivatives
(19)
Middle Aged
(17)
Particle Physics
(17)
Thalidomide - Pharmacology
(17)
Experiment
(16)
Immunology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-a Inhibitor

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells

A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity

Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues

Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner

Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-AT

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Carboxylic acid replacement structure-activity relationships in suosan type sweeteners. A sweet taste antagonist. 1

Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34 super(+) Progenitor Cells

Aktive Filter

Suchergebnisse filtern